80 related articles for article (PubMed ID: 816687)
1. [Evaluation of antibrucellic vaccines in mice].
Valette L; Stellmann C
Dev Biol Stand; 1976; 31():308-13. PubMed ID: 816687
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of antibrucellosis vaccines using guinea pigs].
Le Garrec Y; Pilet C; Garrido-Calderon N
Dev Biol Stand; 1976; 31():301-7. PubMed ID: 816686
[TBL] [Abstract][Full Text] [Related]
3. [Checking of anti-Brucella vaccines by counting the Brucella in the spleen of intraperitoneally innoculated, vaccinated or unvaccinated, mice].
Plommet M; Bosseray N
J Biol Stand; 1977; 5(4):261-74. PubMed ID: 411794
[No Abstract] [Full Text] [Related]
4. Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants.
Grilló MJ; Manterola L; de Miguel MJ; Muñoz PM; Blasco JM; Moriyón I; López-Goñi I
Vaccine; 2006 Apr; 24(15):2910-6. PubMed ID: 16439039
[TBL] [Abstract][Full Text] [Related]
5. A recent trial comparing two 45/20 adjuvant Brucella vaccines.
McKeon FW
Dev Biol Stand; 1976; 31():343-50. PubMed ID: 816690
[TBL] [Abstract][Full Text] [Related]
6. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice.
Vemulapalli R; Contreras A; Sanakkayala N; Sriranganathan N; Boyle SM; Schurig GG
Vet Microbiol; 2004 Sep; 102(3-4):237-45. PubMed ID: 15327798
[TBL] [Abstract][Full Text] [Related]
7. Monophosphoryl lipid A-induced immune enhancement of Brucella abortus salt-extractable protein and lipopolysaccharide vaccines in BALB/c mice.
Tabatabai LB; Pugh GW; Stevens MG; Phillips M; McDonald TJ
Am J Vet Res; 1992 Oct; 53(10):1900-7. PubMed ID: 1456539
[TBL] [Abstract][Full Text] [Related]
8. Killed vaccine in adjuvant and protection of mice against an intraperitoneal challenge of Brucella: kinetic studies.
Pardon P; Marly J
Ann Rech Vet; 1976; 7(4):297-305. PubMed ID: 829301
[TBL] [Abstract][Full Text] [Related]
9. Serological findings obtained in cattle herds immunised with the Brucella melitensis Rev.1 and the B. abortus B19 vaccine in Mongolia.
Dénes B
Acta Vet Hung; 1997; 45(1):33-43. PubMed ID: 9270127
[TBL] [Abstract][Full Text] [Related]
10. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.
Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J
Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242
[TBL] [Abstract][Full Text] [Related]
11. Resistance of Brucella abortus infected mice to intravenous or intraperitoneal Brucella reinfection.
Pardon P; Marly J
Ann Immunol (Paris); 1976; 127(1):57-70. PubMed ID: 821385
[TBL] [Abstract][Full Text] [Related]
12. Unresponsiveness of vaccinated BALB/c mice to a second inoculation of lipopolysaccharide from Brucella abortus strain 2308.
Pugh GW; Phillips M; Tabatabai LB; McDonald TJ
Vet Microbiol; 1991 Jan; 26(1-2):167-77. PubMed ID: 1902610
[TBL] [Abstract][Full Text] [Related]
13. Mouse cytokine profiles associated with Brucella abortus RB51 vaccination or B. abortus 2308 infection.
Pasquali P; Adone R; Gasbarre LC; Pistoia C; Ciuchini F
Infect Immun; 2001 Oct; 69(10):6541-4. PubMed ID: 11553603
[TBL] [Abstract][Full Text] [Related]
14. The use of laboratory animals in the potency test of Brucella abortus S.19 vaccine. Response of guinea-pigs to graduated doses of vaccine and challenge.
Thornton DH; Muskett JC
J Comp Pathol; 1972 Apr; 82(2):201-8. PubMed ID: 4625200
[No Abstract] [Full Text] [Related]
15. Reactivation of a residual Brucella abortus 19 vaccine infection in mice by a virulent challenge or by injection of brucellin or of Brucella lipopolysaccharide.
Plommet M; Plommet AM
Ann Rech Vet; 1988; 19(4):245-51. PubMed ID: 3148291
[TBL] [Abstract][Full Text] [Related]
16. [Phenol-insoluble vaccine against human brucellosis: evaluation of the immunogenic power in guinea pigs].
Bolpe J; de Lapenta DF; García-Carrillo C
Rev Inst Med Trop Sao Paulo; 1991; 33(1):23-7. PubMed ID: 1843392
[TBL] [Abstract][Full Text] [Related]
17. Control methods and thresholds of acceptability for antibrucella vaccines.
Bosseray N
Dev Biol Stand; 1992; 79():121-8. PubMed ID: 1286747
[TBL] [Abstract][Full Text] [Related]
18. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.
Al-Mariri A; Tibor A; Mertens P; De Bolle X; Michel P; Godefroid J; Walravens K; Letesson JJ
Infect Immun; 2001 Aug; 69(8):4816-22. PubMed ID: 11447155
[TBL] [Abstract][Full Text] [Related]
19. Immunogencity of HSA-L7/L12 (Brucella abortus ribosomal protein) in an animal model.
Pakzad I; Rezaee A; Rasaee MJ; Tabbaraee B; Delpisheh A
Iran J Immunol; 2009 Mar; 6(1):12-21. PubMed ID: 19293473
[TBL] [Abstract][Full Text] [Related]
20. [Influence of the mouse genotype on the sensitivity to Brucella abortus 544].
Le Garrec Y; Garrido-Calderon N; Pilet C
Dev Biol Stand; 1976; 31():287-92. PubMed ID: 816685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
